reference/9537601

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9537601

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
endingPage	3637
issn	0732-183X 1527-7755
issueIdentifier	31
pageRange	3626-3637
publicationName	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
startingPage	3626
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_2976b18fac70f564063c2c2fc32b42b7 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_7b06054cb3290cb2ff62e3b094b84de7 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_8cc11d023573ac9823b2bc5c8f051b85
bibliographicCitation	Rogers KA, Huang Y, Ruppert AS, Abruzzo LV, Andersen BL, Awan FT, Bhat SA, Dean A, Lucas M, Banks C, Grantier C, Heerema NA, Lozanski G, Maddocks KJ, Valentine TR, Weiss DM, Jones JA, Woyach JA, Byrd JC. Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2020 Nov 01;38(31):3626–37. PMID: 32795224; PMCID: PMC7605394.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6b03465a26ed58b4425a0ea25d904ffc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5334f0aba66a915ab394a81f58b6a3a0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f66ab640a0521794a57ea369ea04078e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_23a4519ec3f2513b4cb52fbefd7ba016 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_61ba17938993492d4ab8132fff5bfe6f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_372727f914481fcc9c9d1b3847958930 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fece62dd4ef8a9f5a50d9a86a99e34ec http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c341988e8599008a45820ebade28cd23 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_83b54e5598a5b23aef16a8f23618aa7d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_33ce226c46aca77391cb130a87092406 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ca6864ab9f5a73400ab9db5efc66c455 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8093e7d95d0a8f6d60aa309f1998fbd7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ab7408008e1a24b67eefd8c8ff4902d5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_03561712292ce99a7c4a382a0d092b0a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5084dc1c17851627c8a04a75636864e1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_10524a6e467766904d16d35b07757151 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b529d3d05d0bb41258ccb7cb7b0e4f97 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_98cc0f615ce0f7741a6956f67aaa9468 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a5a9bc27899e22d0f11e60c800b24d0a
date	2020-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1200/jco.20.00491 https://pubmed.ncbi.nlm.nih.gov/PMC7605394 https://pubmed.ncbi.nlm.nih.gov/32795224
isPartOf	https://portal.issn.org/resource/ISSN/0732-183X https://portal.issn.org/resource/ISSN/1527-7755 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5023
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia
discusses	http://id.nlm.nih.gov/mesh/M0028488 http://id.nlm.nih.gov/mesh/M0016885 http://id.nlm.nih.gov/mesh/M0020790 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M000614617 http://id.nlm.nih.gov/mesh/M0582537 http://id.nlm.nih.gov/mesh/M0576729 http://id.nlm.nih.gov/mesh/M0000347
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D003071Q000187 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D015451Q000188 http://id.nlm.nih.gov/mesh/D007694
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D010880Q000008 http://id.nlm.nih.gov/mesh/D055815 http://id.nlm.nih.gov/mesh/D061067Q000008 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D011788 http://id.nlm.nih.gov/mesh/D018365 http://id.nlm.nih.gov/mesh/D018791 http://id.nlm.nih.gov/mesh/D013921Q000139 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D019086Q000008 http://id.nlm.nih.gov/mesh/D005500 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D012074 http://id.nlm.nih.gov/mesh/D015996 http://id.nlm.nih.gov/mesh/D019233 http://id.nlm.nih.gov/mesh/D000077982 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D000225Q000031 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D009503Q000139 http://id.nlm.nih.gov/mesh/D015451Q000097 http://id.nlm.nih.gov/mesh/D013449Q000008 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D006973Q000139 http://id.nlm.nih.gov/mesh/D007010Q000139 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000225Q000008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11445 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10251 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8102 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9720 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID49846579 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24821094

Total number of triples: 90.